HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.

HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.
复制标题

HNRNPH1 稳定的 LINC00662 通过激活 GRP78/p38 通路促进卵巢癌进展。

DOI:
10.1038/s41388-021-01884-5
复制
发表时间:
2021-07
期刊:
影响因子:
8
通讯作者:
Wu X
Wu X
中科院分区:
医学1区
文献类型:
--
作者:
Wu Y;Guo Q;Ju X;Hu Z;Xia L;Deng Y;Zhao P;Zhang M;Shao Y;Huang S;He X;Wen H;Wu X

文献摘要

参考文献

被引文献

相似文献

大量研究表明拷贝数改变(CNA)在癌症进展中发挥着重要作用。然而,卵巢癌(OC)中长基因间非编码RNA(lincRNA)的CNA及其潜在功能尚未得到充分研究。在此,基于对癌症基因组图谱 (TCGA) 数据库的分析,我们在这项研究中鉴定了一种名为 LINC00662 的致癌 lincRNA,其 CNA 与其表达增加之间表现出显着相关性。 LINC00662 过度表达与 OC 患者的恶性特征高度相关,是一个预后指标。 LINC00662 在体外和体内显着促进 OC 细胞增殖和转移。从机制上讲,LINC00662 由异质核核糖核蛋白 H1 (HNRNPH1) 稳定。此外,LINC00662 通过与葡萄糖调节蛋白 78 (GRP78) 相互作用并防止其在 OC 细胞中泛素化来发挥致癌作用,从而激活致癌 p38 MAPK 信号通路。总而言之,我们的结果定义了 LINC00662 在 GRP78/p38 信号传导介导的 OC 进展中的致癌作用,对 OC 的治疗靶点具有潜在影响。
Numerous studies suggest an important role for copy number alterations (CNAs) in cancer progression. However, CNAs of long intergenic noncoding RNAs (lincRNAs) in ovarian cancer (OC) and their potential functions have not been fully investigated. Here, based on analysis of The Cancer Genome Atlas (TCGA) database, we identified in this study an oncogenic lincRNA termed LINC00662 that exhibited a significant correlation between its CNA and its increased expression. LINC00662 overexpression is highly associated with malignant features in OC patients and is a prognostic indicator. LINC00662 significantly promotes OC cell proliferation and metastasis in vitro and in vivo. Mechanistically, LINC00662 is stabilized by heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1). Moreover, LINC00662 exerts oncogenic effects by interacting with glucose-regulated protein 78 (GRP78) and preventing its ubiquitination in OC cells, leading to activation of the oncogenic p38 MAPK signaling pathway. Taken together, our results define an oncogenic role for LINC00662 in OC progression mediated via GRP78/p38 signaling, with potential implications regarding therapeutic targets for OC.
DOI: 10.1074/jbc.m501070200
发表时间: 2005-06-17
影响因子: 4.8
作者:
Garneau, D;Revil, T;Chabot, B
通讯作者: Chabot, B
DOI: 10.1016/j.celrep.2015.12.063
发表时间: 2016-01-26
期刊: Cell reports
影响因子: 8.8
作者:
Grohar PJ;Kim S;Rangel Rivera GO;Sen N;Haddock S;Harlow ML;Maloney NK;Zhu J;O'Neill M;Jones TL;Huppi K;Grandin M;Gehlhaus K;Klumpp-Thomas CA;Buehler E;Helman LJ;Martin SE;Caplen NJ
通讯作者: Caplen NJ
DOI: 10.1038/nature08822
发表时间: 2010-02-18
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1007/s13258-020-01001-y
发表时间: 2020-09-29
期刊: GENES & GENOMICS
影响因子: 2.1
作者:
Cao, Xinling;Zhang, Guanping;Tursun, Turgunjan
通讯作者: Tursun, Turgunjan
DOI: 10.1016/j.canlet.2011.05.022
发表时间: 2011-10-01
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Cohen, Marie;Petignat, Patrick
通讯作者: Petignat, Patrick